Onfasprodil (MIJ821) is a drug delivered via intravenous infusion that is designed as a fast-acting treatment for treatment-resistant depression. It works as a negative allosteric modulator of the NMDA receptor subunit 2B (NR2B). The drug is developed by Novartis.